{"disease":{"id":"extensive-disease","name":"extensive disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04501497","title":"Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)","phase":"","overall_status":"COMPLETED","enrollment_count":1221,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT03043872","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":987,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04818983","title":"The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)","phase":"","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT04666961","title":"Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":262,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT04449861","title":"Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04712903","title":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04055792","title":"Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03983759","title":"Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07061535","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06758700","title":"Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}